STILOZ 50

AboutSTILOZ 50 contains Cilostazol 50mg, a phosphodiesterase-3 (PDE3) inhibitor primarily used for the symptomatic management of intermittent claudication in patients with peripheral artery disease (PAD). Cilostazol works by inhibiting PDE3, which leads to an increase in intracellular cyclic AMP (cAMP) levels in platelets and vascular smooth muscle cells. This results in potent antiplatelet effects, reducing platelet aggregation, and direct arterial vasodilation, particularly in the femoral circulation. By improving blood flow to the legs and reducing platelet aggregation, Cilostazol helps to alleviate the pain and cramping experienced during exercise, thereby increasing walking distance and improving the quality of life for patients with intermittent claudication. It is a distinct therapeutic agent that addresses both the circulatory and thrombotic aspects of PAD, offering a targeted approach to symptom relief and functional improvement.UsesSymptomatic management of intermittent claudicationImproving walking distance in patients with peripheral artery diseaseEnhancing quality of life in PAD patientsReduction of leg pain and cramping during exerciseDirections For UseTake orally twice daily, at least 30 minutes before or 2 hours after breakfast and dinner.BenefitsSignificantly improves maximum and pain-free walking distanceReduces symptoms of intermittent claudicationEnhances overall quality of life for PAD patientsPossesses both antiplatelet and vasodilatory propertiesOffers a targeted treatment for peripheral artery diseaseMay reduce the need for revascularization proceduresSide EffectsHeadacheDiarrhea or abnormal stoolsPalpitations or tachycardiaDizzinessNausea or abdominal painPeripheral edema (swelling)Rhinitis or pharyngitisDyspepsia (indigestion)Ecchymosis (bruising)InfectionVertigoChest painSafety MeasuresAlcohol - Alcohol may increase the risk of dizziness and headache. Use with caution.Pregnancy - Not recommended during pregnancy; use only if potential benefit outweighs potential risk to the fetus.Breastfeeding - Not recommended; it is unknown if Cilostazol is excreted in breast milk.Liver - Use with caution in patients with hepatic impairment; dose adjustment may be needed.Kidney - Use with caution in severe renal impairment; dose adjustment may be needed.Lung - Contraindicated in patients with heart failure of any severity due to increased mortality risk.DisclaimerMedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.Our goal is to complement, not replace, the essential doctor-patient relationship.